Seeking Alpha

Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y...

Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y as sales rose less than expected. The company blames the shortfall on a weakness in its U.S. market, where sales fell roughly 1%. Sales were stronger abroad, rising about 3%. Sales in its vascular business, its largest, were down 2.7%, while its urology unit posted a 3.2% rise. The company also announced plans to acquire privately held Neomend, a developer of sprayable surgical sealants and anti-adhesion products, for $140M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|